Answers are grounded in this paper and cite their sources.
Osteoarthritis (OA) is a degenerative joint disease characterized by chronic inflammation and progressive cartilage erosion. Effective biological treatments for OA often rely on the intra-articular and sustained release of therapeutic agents. In this study, we utilized a self-assembling RADA peptide hydrogel loaded with bone morphogenetic protein-2-derived peptide, termed RB, either alone or combined with the Ca 2 ⁺/calmodulin-dependent kinase inhibitor KN93, forming RBK. We investigated the effects of RB and RBK on chondrocyte apoptosis, inflammation, and M1 macrophage polarization, as well as their therapeutic efficacy in a mouse model of destabilization of the medial meniscus (DMM)-induced knee osteoarthritis (KOA). Both RB and RBK reduced H 2 O 2 -induced chondrocyte apoptosis. KN93 and RBK, significantly inhibited IL-1β-induced expression of inflammatory cytokines (TNF-α, IL-6), enzymes (COX-2, iNOS), and matrix-degrading metalloproteinases (MMP-3, MMP-13). RNA sequencing indicated that KN93 treatment is associated with enrichment of lipid and cholesterol metabolism–associated genes, including SCD, MSMO1, and HMGCS1, under inflammatory conditions. Moreover, KN93 alone and RBK markedly suppressed lipopolysaccharide-induced M1 macrophage polarization. In vivo, intra-articular administration of the RBK hydrogel significantly decreased chondrocyte apoptosis, cartilage degradation, and M1 macrophage infiltration in DMM-induced KOA. Collectively, these findings indicate that the RBK hydrogel integrates complementary, component-specific mechanisms-BMP-2-derived peptide-mediated suppression of chondrocyte apoptosis together with KN93-mediated anti-inflammatory and macrophage-modulatory effects—and offers a promising therapeutic platform for the intra-articular treatment of KOA.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: